Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update

It has been estimated by the World Health Organization (WHO) that over 71 million people were infected with the hepatitis C virus (HCV) in 2015. Since then, a number of highly effective direct-acting antiviral (DAA) regimens have been licensed for the treatment of chronic HCV infection: sofosbuvir/d...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolders, Elise J., Jansen, Anouk M. E., ter Horst, Peter G. J., Rockstroh, Jürgen, Back, David J., Burger, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768915/
https://www.ncbi.nlm.nih.gov/pubmed/31114957
http://dx.doi.org/10.1007/s40262-019-00774-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768915/
https://www.ncbi.nlm.nih.gov/pubmed/31114957
http://dx.doi.org/10.1007/s40262-019-00774-0

Ejemplares similares